StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
Pfizer Inc.
NYSE:PFE
Sector
Location
Market Cap
USD 140.94 B
Share Price
USD 24.79
Avg Daily Volume
44,965,832
Change (1 day)
-2.21%
Change (1 year)
-17.86%
Change (YTD)
-6.56%
Pfizer Inc. Enterprise Value to EBITDA (EV/EBITDA) on July 25, 2025: 11.17
Pfizer Inc. Enterprise Value to EBITDA (EV/EBITDA) is 11.17 on July 25, 2025, a -72.32% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
-
Pfizer Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 41.67 on July 25, 2025, which is 272.94% above the current Enterprise Value to EBITDA (EV/EBITDA).
-
Pfizer Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 10.16 on July 25, 2025, which is -9.10% below the current Enterprise Value to EBITDA (EV/EBITDA).
-
Pfizer Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 17.75.
Competitors
Eli Lilly and Company
USD 812.69
LLY
+7.26
0.90%
AbbVie Inc.
USD 190.28
ABBV
-0.55
-0.29%
Roche Holding AG
USD 345.06
RO.SW
-6.70
-1.91%
AstraZeneca PLC
USD 145.14
AZN.L
-2.14
-1.46%
Merck & Co., Inc.
USD 84.71
MRK
+0.60
0.71%
Amgen Inc.
USD 306.58
AMGN
-1.97
-0.64%
Gilead Sciences, Inc.
USD 116.20
GILD
+3.00
2.65%
Sanofi
USD 99.93
SAN.PA
-0.18
-0.18%
Bristol-Myers Squibb Company
USD 48.43
BMY
-0.51
-1.04%
Chugai Pharmaceutical Co., Ltd.
USD 49.71
4519.T
+0.51
1.03%
GSK plc
USD 18.71
GSK.L
-0.07
-0.36%
Regeneron Pharmaceuticals, Inc.
USD 563.10
REGN
-1.54
-0.27%
Cencora, Inc.
USD 290.36
COR
-0.09
-0.03%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.87
600276.SS
-0.17
-2.10%
Takeda Pharmaceutical Company Limited
USD 29.30
4502.T
-0.27
-0.91%
Haleon plc
USD 4.91
HLN.L
-0.02
-0.37%
Daiichi Sankyo Company, Limited
USD 24.58
4568.T
-0.34
-1.36%
Ucb S.A.
USD 209.16
UCB.BR
-1.00
-0.47%
BeOne Medicines Ltd.
USD 291.47
ONC
-4.99
-1.68%
Hansoh Pharmaceutical Group Company Limited
USD 4.37
3692.HK
+0.02
0.44%
Key Data
| Date | Enterprise Value to EBITDA (EV/EBITDA) | Free Cash Flow Yield | Dividend Yield | Market Capitalization |
|---|
Competitors
Eli Lilly and Company
USD 812.69
LLY
+7.26
0.90%
AbbVie Inc.
USD 190.28
ABBV
-0.55
-0.29%
Roche Holding AG
USD 345.06
RO.SW
-6.70
-1.91%
AstraZeneca PLC
USD 145.14
AZN.L
-2.14
-1.46%
Merck & Co., Inc.
USD 84.71
MRK
+0.60
0.71%
Amgen Inc.
USD 306.58
AMGN
-1.97
-0.64%
Gilead Sciences, Inc.
USD 116.20
GILD
+3.00
2.65%
Sanofi
USD 99.93
SAN.PA
-0.18
-0.18%
Bristol-Myers Squibb Company
USD 48.43
BMY
-0.51
-1.04%
Chugai Pharmaceutical Co., Ltd.
USD 49.71
4519.T
+0.51
1.03%
GSK plc
USD 18.71
GSK.L
-0.07
-0.36%
Regeneron Pharmaceuticals, Inc.
USD 563.10
REGN
-1.54
-0.27%
Cencora, Inc.
USD 290.36
COR
-0.09
-0.03%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.87
600276.SS
-0.17
-2.10%
Takeda Pharmaceutical Company Limited
USD 29.30
4502.T
-0.27
-0.91%
Haleon plc
USD 4.91
HLN.L
-0.02
-0.37%
Daiichi Sankyo Company, Limited
USD 24.58
4568.T
-0.34
-1.36%
Ucb S.A.
USD 209.16
UCB.BR
-1.00
-0.47%
BeOne Medicines Ltd.
USD 291.47
ONC
-4.99
-1.68%
Hansoh Pharmaceutical Group Company Limited
USD 4.37
3692.HK
+0.02
0.44%